Gastric Cancer | Topics

FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
April 16, 2021

The agency approved nivolumab in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, making it the first approved first-line immunotherapy for this patient population.

Nivolumab Plus Paclitaxel Shows Clinical Activity in Advanced Gastric Cancer Subgroup
April 10, 2021

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

Trastuzumab Deruxtecan Sensitivity Associated With Various Levels of HER2-Expressing Gastric Cancer Cells
April 10, 2021

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.